Cantab Pharmaceuticals
Article Abstract:
Cantab Pharmaceuticals has two main products which are vaccines to potect against genital warts and herpes. The company has not benefited from renewed interest in biotech firms, and its work on therapeutic vaccines may be little understood. The company has sometimes had problems with its development schedules, and is involved in a patent dispute with the US university. The management is involved in deals which aim to make the company profitable at an earlier stage, and the company benefits from major pharmaceutical companies as partners.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Cantab Pharmaceuticals
Article Abstract:
Cantab Pharmaceuticals carried out a share placing in Jul 1996 that raised 25.7 million pounds sterling. The company has received a first payment of 7 million pounds for vaccine development rights from SmithKline Beecham. Cantab should receive an additional 17 million pounds though the vaccine is not likely to be marketed until 1998. There are additional products being developed. The company saw a drop in revenue after the end of contract development fees paid by Baxter Healthcare to 1995.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Merck and Co
Article Abstract:
Merck saw a rise in growth of both profits and sales for 3rd qtr 1996 with new products doing well in addition to established drugs. The company's Mecavor and Zocor cholesterol-lowering products account for some 20% of turnover and Zocor is increasing sales by over 25% annually. Merck is seen as performing well both in terms of research and marketing. Merck owns Merck-Medco Managed Care which has seen a rse in sales of over 25% in 1996. The company's shares may cease to rise over the short term but are likely to perform well in the long term.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Powderject Pharmaceuticals. Powderject. PowderJect Pharmaceuticals
- Abstracts: Capital appreciation. Snakes and ladders. High rise living
- Abstracts: 3 secrets to motivating sales. Nerds rule. Freeze frame
- Abstracts: Moving toward missile defense. Communicating underwater. U.S. Army goes expeditionary
- Abstracts: Too many holidays mean a dark summer for UK tour operators. Price war sparked by operators' scramble for First Choice